Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Oncolytics Biotech (ONC:CN) (ONCY) PT Lowered to Cdn$10 at RBC Capital
March 12, 2019 7:27 AM EDTRBC Capital analyst Douglas Miehm lowered the price target on Oncolytics Biotech (ONC:CN) (NASDAQ: ONCY) to Cdn$10.00 (from Cdn$11.00) while maintaining a Outperform rating.
no surprises in Q4/18 results as the company continues to make clinical progress.... More